Avadel Pharmaceuticals-adr (AVDL) 주식
헬스케어 부문 기업. 11월 2026 기준 Avadel Pharmaceuticals-adr의 주가, 사업 개요, 알아두어야 할 핵심 정보를 정리했습니다.
Avadel Pharmaceuticals plc (ticker: AVDL) is a specialty pharmaceutical company focused on developing and commercialising treatments for rare and sleep-related disorders. With a market capitalisation of about $1.74 billion, Avadel combines a commercial-stage product strategy with a pipeline of clinical candidates. Key things investors should know include reliance on regulatory approvals and successful product launches, potential for meaningful upside if late-stage trials and market uptake succeed, and exposure to competition from larger pharma players. Financial outcomes can swing with milestone events, pricing pressure, and patent or manufacturing challenges. Biotech stocks can be volatile around clinical readouts and regulatory news. Before considering exposure, investors should review the company’s recent financial reports, cash runway, commercial performance metrics and regulatory timelines. This summary is general educational information and not personal financial advice; suitability depends on your individual goals, risk tolerance and time horizon, so consult a qualified adviser if needed.
Avadel Pharmaceuticals-adr (AVDL) 주식 전망
애널리스트 목표 주가, 향후 12개월
$21.06
-2.7% 오늘 $21.64 대비
최근 12개월 가격 범위
12개월 최고가에 근접
Avadel Pharmaceuticals-adr을(를) 담당하는 애널리스트들의 12개월 컨센서스 목표 주가는 $21.06으로, 현재가 $21.64 대비 낮은 수준입니다.
애널리스트 목표 주가는 의견이며 보장이 아닙니다. 원금 손실 위험이 있습니다. 25 5월 2026 기준 데이터입니다.
출처: 애널리스트 심리 지표는 4만 곳 이상의 기업 고객을 보유한 글로벌 금융 시장 데이터 선두 기업 Refinitiv Ltd가 제공합니다. Refinitiv Ltd는 Nemo와 무관한 독립적인 제3자입니다. 본 내용은 투자 조언이 아닙니다.
6개월 성장 성과
주가 성과 요약
애널리스트 평가
Analysts suggest holding Avadel Pharmaceuticals' stock, predicting slight decline in its value.
재무 건전성
Avadel Pharmaceuticals is generating strong revenue and high profit margins, indicating good financial stability.
앱을 무료로 다운로드하고 더 많은 종목 보기
60초면 충분합니다.
AVDL이(가) 포함된 바스켓
Injectable Drug Revolution: What's Next Beyond Pills?
The UK's approval of GSK's long-acting HIV drug marks a pivotal shift from daily pills to less frequent injections. This theme focuses on the pharmaceutical innovators leading the charge in developing and commercializing long-acting therapeutic technologies.
게시일: 2025년 10월 17일
바스켓 살펴보기The Global Weight-Loss Drug Price Shift
Eli Lilly's significant price hike for Mounjaro in the UK, driven by U.S. political pressure, highlights a new global pricing strategy for blockbuster drugs. This creates a potential opportunity for competitors in the booming weight-loss market as patients and providers may seek more affordable alternatives.
게시일: 2025년 8월 15일
바스켓 살펴보기Next-Generation Drug Delivery Systems
This carefully selected group of stocks represents innovative companies revolutionizing how medications are delivered to patients. Handpicked by our professional analysts, these firms are developing technologies that make treatments simpler, more effective, and user-friendly, creating meaningful investment potential in an evolving healthcare landscape.
게시일: 2025년 7월 18일
바스켓 살펴보기이 종목을 주목해야 하는 이유
Pipeline-driven growth
Late-stage clinical readouts and approvals can materially move the story, though outcomes are uncertain and can cause volatility.
Speciality market focus
Targeting rare and sleep disorders can mean concentrated market opportunities, but commercial success depends on uptake and payer support.
Regulatory catalysts
Upcoming regulatory milestones and launches are potential catalysts, balanced by the risk of delays or unfavourable decisions.
왜 Nemo와 함께 투자해야 할까요?
수수료 무료
주식, ETF 등을 수수료 없이 거래하세요. 수익을 더 많이 지키세요.
신뢰할 수 있는 규제 기관 인가
2015년부터 Exinity Group의 일원으로, 전 세계 100만 명 이상의 고객에게 서비스를 제공합니다.